RA
PTGX icon

Royce & Associates’s Protagonist Therapeutics PTGX Stock Holding History

Royce & Associates’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-14,349
Closed -$1.51M – 816
2026
Q1 		$1.51M Sell
14,349
-2,640
-16% -$234K 0.01% 618
2025
Q4 		$1.48M Hold
16,989
– – 0.02% 634
2025
Q3 		$1.13M Buy
16,989
+4,734
+39% +$269K 0.01% 649
2025
Q2 		$677K Hold
12,255
– – 0.01% 701
2025
Q1 		$593K Buy
+12,255
New +$514K 0.01% 719

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Royce & Associates's PTGX Position: Q2 2026 in Review

Royce & Associates sold out of Protagonist Therapeutics (PTGX) in Q2 2026, closing a stake of 14,349 shares — an estimated $1.51M sold.

Royce & Associates first reported a position in PTGX in Q1 2025 and held it in 5 quarters. The position peaked at $1.51M in Q1 2026. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Royce & Associates reported no remaining Protagonist Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Royce & Associates sold 14,349 Protagonist Therapeutics shares in Q2 2026, an estimated $1.51M.
  • Royce & Associates first reported a position in Protagonist Therapeutics in Q1 2025 and held it in 5 quarters.
  • Royce & Associates's Protagonist Therapeutics position peaked at $1.51M in Q1 2026.
  • 343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.